Market Overview

FDA Approves Fulyzaq 125 mg Delayed-Release Tablets for Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy

Salix Pharmaceuticals (NASDAQ: SLXP) today announced that the Food
and Drug Administration has approved Fulyzaq (crofelemer) 125 mg
delayed-release tablets for the symptomatic relief of non-infectious
diarrhea in adult patients with human immunodeficiency virus (HIV)/
acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy
(ART).

“The FDA approval of Fulyzaq is a significant step forward in
addressing the unmet medical need of people with HIV/AIDS on ART who
experience non-infectious diarrhea, which often can lead to reduced
treatment compliance,” said Carolyn Logan, President and CEO of Salix.
“Since the introduction of antiretroviral therapy, people with HIV are
living longer and thus medication compliance and tolerability as well as
quality

See full press release

Posted-In: News Guidance Management

 

Related Articles (SLXP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters